Texas Digestive Disease Consultant - Ft Worth
Welcome,         Profile    Billing    Logout  
 16 Trials 
20 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Loomba, Rohit
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
NCT05677971: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Recruiting
3
160
Europe, Canada, US, RoW
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo, Sodium chloride
Takeda, Takeda Development Center Americas, Inc.
Alpha1-Antitrypsin Deficiency
03/27
03/29
RAMIC, NCT04366050: Ramipril for the Treatment of COVID-19

Completed
2
160
US
Ramipril 2.5 MG Oral Capsule, Ramipril, Placebo oral capsule, Placebo
University of California, San Diego, Pfizer
COVID-19
05/21
05/21
VEDS, NCT04801849: Vitamin E Dosing Study

Active, not recruiting
2
200
US
Vitamin E, d-alpha-tocopherol, Placebo
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Duke University, Liver Institute Northwest, Indiana University, St. Louis University, University of California, San Diego, University of Southern California, University of California, San Francisco, Virginia Commonwealth University, The Cleveland Clinic
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
03/25
09/25
ELPISII, NCT04925024: Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.

Recruiting
2
38
US
Lomecel-B medicinal signaling cells
Longeveron Inc., National Heart, Lung, and Blood Institute (NHLBI), Ann & Robert H Lurie Children's Hospital of Chicago, The University of Texas Health Science Center, Houston
Hypoplastic Left Heart Syndrome
03/25
08/25
SAMARA, NCT06005012: Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM

Recruiting
2
120
US
Semaglutide, Placebo
University of California, San Diego
Fibrosis, Liver, Type 2 Diabetes Mellitus in Obese, Non-Alcoholic Fatty Liver Disease
03/25
06/25
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects

Recruiting
2
240
US, RoW
HM15211, Placebo of HM15211
Hanmi Pharmaceutical Company Limited
NASH - Nonalcoholic Steatohepatitis
05/26
11/26
HORIZON, NCT05583344 / 2022-002538-14: Phase 2b Study of GSK4532990 in Adults With NASH

Active, not recruiting
2
271
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
12/25
03/26
LCN RESCU, NCT05832229: Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

Recruiting
2
256
US
Rosuvastatin, Rosuvastatin 20 mg, Rosuvastatin 10 mg
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The Cleveland Clinic, Columbia University, Weill Medical College of Cornell University, Duke University, Mayo Clinic, University of Miami, University of Michigan, University of California, San Diego, University of California, San Francisco, LAC+USC Medical Center, Virginia Commonwealth University, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Cancer Institute (NCI), University of Southern California
Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis Due to Hepatitis C
11/26
11/26
NCT04483947: A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients

Completed
1
74
US
AZD2693, Placebo
AstraZeneca, Parexel
Non-alcoholic Steatohepatitis (NASH)
12/23
12/23
NCT04736966: Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease

Completed
1
13
US
Guselkumab 30mg, Tremfya, Guselkumab 70mg, Guselkumab 100mg
University of California, San Diego
Alcoholic Liver Disease
03/24
03/24
NCT02124577: Development of Kinetic Biomarkers of Liver Fibrosis Measuring NAFLD

Recruiting
N/A
50
US
University of California, San Diego, KineMed
Non-alcoholic Fatty Liver Disease
05/21
05/21
NCT01643512: Heritability of Fatty Liver as Measured by MRI: a Cross Sectional Study of Twins and Family Members

Recruiting
N/A
500
US
University of California, San Diego
Liver Disease
08/21
08/21
NCT04454463: Nonalcoholic Fatty Liver Disease (NAFLD) Database 3

Active, not recruiting
N/A
1640
US
Johns Hopkins Bloomberg School of Public Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Baylor College of Medicine, Case Western Reserve University, Duke University, Ann & Robert H Lurie Children's Hospital of Chicago, Indiana University, Liver Institute Northwest, Seattle Children's Hospital, St. Louis University, University of California, San Diego, University of California, San Francisco, University of Southern California, Virginia Commonwealth University, Emory University, Children's Hospital Medical Center, Cincinnati
Liver Diseases
06/25
06/25
NCT04795219: Prevalence and Predictors of Hepatic Steatosis in Persons Living With HIV

Recruiting
N/A
1250
US
University of California, San Francisco, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NAFLD, NAFLD-HIV, Hiv
01/25
01/25
NCT05023044: Nonalcoholic Fatty Liver Disease in HIV Database

Recruiting
N/A
400
US
Johns Hopkins University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NAFLD, NASH - Nonalcoholic Steatohepatitis, Hiv
01/26
01/26
NCT02014415: Alpha-1 Antitrypsin Deficiency Adult Liver Study

Active, not recruiting
N/A
120
US
Liver Biopsy (Biopsy Group Only)
St. Louis University, Alpha-1 Foundation, University of California, Boston University, University College, London, University of Massachusetts, Worcester
Alpha-1 Antitrypsin Deficiency
07/25
07/26
LCN-C, NCT05740358: Liver Cirrhosis Network Cohort Study

Recruiting
N/A
1200
US
Northwestern University, The Cleveland Clinic, Columbia University, Weill Medical College of Cornell University, Duke University, Mayo Clinic, University of Miami, University of Michigan, University of California, San Diego, University of California, San Francisco, LAC+USC Medical Center, Virginia Commonwealth University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Cancer Institute (NCI), University of Southern California, Central Virginia Veterans Healthcare System
Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis, Biliary, Cirrhosis Cryptogenic, Cirrhosis Due to Hepatitis C, Cirrhosis Due to Primary Sclerosing Cholangitis
09/27
09/28
Modi, Apurva A
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
NCT04339621: AIH Risk Stratification With Multiparametric MRI

Terminated
N/A
11
US
LiverMultiscan
Perspectum
Autoimmune Hepatitis
09/21
04/23

Download Options